Greg Pyszczymuka - 31 Dec 2023 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role: Chief Commercial Officer
Signature: /s/ Mark Oki as attorney-in-fact for Greg Pyszczymuka
Issuer symbol: AYTU
Transactions as of: 31 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Jan 2024, 16:37:59 UTC
Previous filing: 03 Oct 2023
Next filing: 02 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AYTU	Common Shares	Options Exercise		+209	+0.94%		22,560	31 Dec 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AYTU	Restricted Stock Units	Options Exercise	$0	-209	-17%	$0.000000	1,042	31 Dec 2023	Common Shares	209		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.